Jefferies analyst Biren Amin sees further upside potential for Neurocrine Biosciences in 209 despite recent sell-side downgrades on a lack of catalysts. Ingrezza's 2019 sales should come in above consensus, Amin tells investors in a research note. Despite the recent trial failure in Tourette's, the "setup continues to work" for Neurocrine on the Ingrezza sales trajectory and new Orilissa royalty stream, Amin tells investors in a research note. He sees a buying opportunity and current share levels and raised his price target for the stock to $110 from $110 while keeping a Buy rating on the name.